Vasopressin is described on its US label as "a polypeptide hormone", and the product is a "sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration".1 The Vasostrict label (Par Health USA, initial US approval 2014) gives one use: "to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines".1 The app lists vasopressin as an antidiuretic hormone, abbreviated ADH, with a subcutaneous route and a 1 IU dose; the label read for this entry describes intravenous use in shock and gives rates in units per minute, so the app's route and dose figures are not figures the label reports.1 The app grades the evidence for vasopressin as strong. The evidence described below comes from the US label, three randomised trials and one individual patient data meta-analysis in shock, a retrospective study of hyponatremia in infants, and the WADA Prohibited List.2,3,5,6,7

2

How it works

Sources in this part

  1. 1Par Health USA, 2026

The label says vasopressin "causes vasoconstriction by binding to V1 receptors on vascular smooth muscle", and that it "stimulates antidiuresis via stimulation of V2 receptors which are coupled to adenyl cyclase".1 It adds that "at lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V2 receptors".1 In patients with vasodilatory shock, the label states that therapeutic doses increase systemic vascular resistance and mean arterial blood pressure and reduce norepinephrine dose requirements, and that vasopressin "tends to decrease heart rate and cardiac output".1 The label reports that the pressor effect is proportional to the infusion rate and that "There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients."1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.3 h
Bioavailability
100%
Typical dose
1 IU
Route
SubQ
Time to peak
~0.2 h

Sources in this part

  1. 1Par Health USA, 2026

The second column of the table holds the app's figures, shown beside what the US label reports for intravenous infusion in vasodilatory shock.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureVasostrict label
Half-life~0.3 h (about 18 minutes)Apparent t1/2 of 10 minutes or less at infusion rates of 0.01 to 0.1 units/minute in vasodilatory shock1
Bioavailability100% by subcutaneous routeNo bioavailability figure is stated in the label text read; the product is for intravenous use1
Time to peak~0.2 hPressor effect reaches its peak within 15 minutes1
Duration1 hPressor effect fades within 20 minutes after the infusion is stopped1
Volume of distributionNot listed140 mL/kg1
ClearanceNot listed9 to 25 mL/min/kg in patients with vasodilatory shock at 0.01 to 0.1 units/minute1

The app's half-life of 0.3 hours is about 18 minutes, longer than the label's "≤10 minutes", which is a bound for infusion rates used in shock.1 The label states that plasma concentrations "increase linearly with increasing infusion rates from 10 to 200 μU/kg/min" and that steady state plasma concentrations "are achieved after 30 minutes of continuous intravenous infusion".1 On metabolism and excretion the label says "Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine", and that it "does not appear to bind plasma protein".1 In pregnancy, "by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold", returning to preconception baseline within two weeks after delivery.1 No interval chart is drawn: the label describes continuous infusion with titration, not a repeated dosing interval.1

4

Human studies

The trials below compared vasopressin with norepinephrine in vasodilatory shock, either in septic shock or after cardiac surgery. The VASST and VANCS records describe infusions of the study drugs, and the VANCS II record names an ICU of a tertiary care hospital as its setting; the route is not stated in the records read.

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Russell and colleagues, VASST, New England Journal of Medicine 20082Multicenter, randomized, double-blind; vasopressin versus norepinephrine, each added to open-label vasopressors2778 patients with septic shock receiving at least 5 microg of norepinephrine per minute (396 vasopressin, 382 norepinephrine)2Vasopressin 0.01 to 0.03 U per minute or norepinephrine 5 to 15 microg per minute; mortality at 28 days228-day mortality 35.4% with vasopressin and 39.3% with norepinephrine (P=0.26); 90-day 43.9% and 49.6% (P=0.11); serious adverse events 10.3% and 10.5% (P=1.00)2
Hajjar and colleagues, VANCS, Anesthesiology 20173Prospective, randomized, double-blind; single hospital (Heart Institute, University of Sao Paulo)3330 adults with vasoplegic shock after cardiac surgery randomized; 300 infused (149 vasopressin, 151 norepinephrine)3Vasopressin 0.01 to 0.06 U/min or norepinephrine 10 to 60 μg/min; composite outcome within 30 days3Composite of mortality or severe complications in 32% with vasopressin and 49% with norepinephrine (unadjusted hazard ratio 0.55; 95% CI 0.38 to 0.80; P = 0.0014); atrial fibrillation 63.8% against 82.1% (P = 0.0004); no difference in digital ischemia, mesenteric ischemia, hyponatremia or myocardial infarction3
Hajjar and colleagues, VANCS II, Critical Care Medicine 20195Single-center, randomized, double-blind; vasopressin versus norepinephrine as first-line vasopressor5250 adults aged 18 or older with cancer and septic shock5Dose not stated in the PubMed record read; mortality at 28 days528-day mortality 71 patients (56.8%) with vasopressin and 66 (52.8%) with norepinephrine (p = 0.52); 90-day 72.0% and 75.2% (p = 0.56); no significant differences in adverse events or SOFA score5
Nagendran and colleagues, individual patient data meta-analysis, Intensive Care Medicine 20196Systematic review and meta-analysis of randomised trials of vasopressin versus any other vasoactive comparator61453 adults with septic shock in four trials6Trials identified up to January 2019; 28-day mortality628-day mortality RR 0.98 (95% CI 0.86-1.12); serious adverse events RR 1.02 (95% CI 0.82-1.26); digital ischaemia absolute risk difference 1.7% (95% CI 0.3%-3.2%); arrhythmias -2.8%6
Bradford and colleagues, Annals of Pharmacotherapy 20237Retrospective case-control study at one tertiary care hospital; each case matched to two controls7142 infants after cardiac surgery who received vasopressin for 6 hours or more; 20 developed hyponatremia, matched with 40 controls7Vasopressin duration compared between cases and controls; dose not stated in the PubMed record read7Hyponatremia in 20 of 142 (14.1%); median sodium nadir 128.5 mEq/L in cases against 142.0 in controls; each extra hour of vasopressin raised the odds by 5% (adjusted odds ratio 1.05)7

Deeper analysis: VASST

Russell and colleagues, writing for the VASST Investigators in the New England Journal of Medicine in 2008, tested whether "low-dose vasopressin as compared with norepinephrine would decrease mortality among patients with septic shock who were being treated with conventional (catecholamine) vasopressors".2 The study drug was given in addition to open-label vasopressors, and all infusions were "titrated and tapered according to protocols to maintain a target blood pressure".2 The authors concluded that low-dose vasopressin "did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were treated with catecholamine vasopressors".2 In the prospectively defined stratum of less severe septic shock, 28-day mortality was 26.5% with vasopressin and 35.7% with norepinephrine (P=0.05); in the more severe stratum it was 44.0% and 42.5% (P=0.76), and "a test for heterogeneity between these two study strata was not significant (P=0.10)".2 PubMed lists the article's publication types as including "Research Support, Non-U.S. Gov't"; the funding statement, the authors' ties to any manufacturer and the authors' own limitations section were not in the PubMed record, so they are not reported.2

Deeper analysis: VANCS

Hajjar and colleagues at the Heart Institute, University of Sao Paulo, reported VANCS in Anesthesiology in 2017, with vasoplegic shock after cardiac surgery as the setting and a 30-day composite of mortality or severe complications as the primary endpoint.3 Of 330 patients randomized, 300 were infused with a study drug.3 The authors' conclusion is that vasopressin "can be used as a first-line vasopressor agent in postcardiac surgery vasoplegic shock and improves clinical outcomes".3 The ClinicalTrials.gov entry for the trial names the University of Sao Paulo as the principal investigator's affiliation and lead sponsor, lists quadruple masking, and carries the status "UNKNOWN" with last known status "RECRUITING" and a verification date of 2013-02.4 The registry entry describes a secondary safety outcome in which adverse events were categorized as "arrhythmias, myocardial necrosis, skin necrosis, ischemia in limbs or distal extremities, or secondary infections", and lists "severe hyponatremia" among its exclusion criteria.4 PubMed lists the publication types as including "Research Support, Non-U.S. Gov't"; the authors' own limitations and any ties to a drug manufacturer were not in the PubMed record, so they are not reported.3

Deeper analysis: VANCS II

Hajjar and colleagues reported VANCS II in Critical Care Medicine in 2019, a "single-center, randomized, double-blind clinical trial" in an intensive care unit of a tertiary care hospital, together with an updated meta-analysis of randomized trials.5 The prespecified secondary outcomes included 90-day mortality, days alive and free of advanced organ support, and SOFA score at 24 and 96 hours, and the authors also measured adverse effects over 28 days.5 The result for the primary outcome was null: 56.8% against 52.8% (p = 0.52).5 The authors concluded that in cancer patients with septic shock, vasopressin as first-line vasopressor therapy "was not superior to norepinephrine in reducing 28-day mortality rate".5 The PubMed record lists grants from the Department of Health (NIHR/CS/009/007, PB-PG-0610-22350 and RP-2015-06-018); the record read does not state a manufacturer sponsor or the authors' own limitations.5

Deeper analysis: the individual patient data meta-analysis

Nagendran and colleagues pooled individual patient data from four randomised trials in adults with septic shock (1453 patients), with a protocol registered on PROSPERO (CRD42017071698), and report no effect on 28-day mortality (RR 0.98, 95% CI 0.86-1.12) or serious adverse events (RR 1.02, 95% CI 0.82-1.26).6 Vasopressin "led to more digital ischaemia" (absolute risk difference 1.7%, 95% CI 0.3%-3.2%) but fewer arrhythmias (-2.8%, 95% CI -0.2% to -5.3%), while mesenteric ischaemia and acute coronary syndrome events "were similar between groups".6 The reduced need for renal replacement therapy (RR 0.86, 95% CI 0.74-0.99) was, in the authors' words, "not robust to sensitivity analyses", and no pre-defined subgroup interaction was statistically significant.6 The authors qualify their result: vasopressin therapy in septic shock "had no effect on 28-day mortality although the confidence intervals are wide".6 The PubMed record lists Department of Health grants (NIHR/CS/009/007 and PB-PG-0610-22350), and its author list includes Russell JA and Walley KR, who are also listed authors of VASST, and Hajjar L, first author of VANCS and VANCS II.6,2,3 No author statement on ties to a drug manufacturer was in the record read.6

Deeper analysis: hyponatremia in infants after cardiac surgery

Bradford and colleagues, with listed affiliations at the University of Oklahoma, studied vasopressin-induced hyponatremia in infants under 6 months after cardiac surgery at a tertiary care, academic hospital, reporting in the Annals of Pharmacotherapy in 2023.7 The authors state that "Hyponatremia is a noted adverse event, but incidence and risk factors remain undefined", and report that 20 of 142 infants (14.1%) developed it.7 The authors report that a "significantly higher number of cases received corticosteroids, loop diuretics, and chlorothiazide versus controls".7 They conclude that vasopressin duration "was independently associated with hyponatremia development".7 The design is retrospective, with 1:2 matching, so the association is not a randomised comparison; the record read states no funding source or limitations section.7

5

Doses reported in studies and on labels

The table lists infusion rates as the sources report them; the app's figure of 1 IU by the subcutaneous route is not among them.

Table 5.1Doses reported in studies and on labels6 rows
SourceSetting and comparatorDose and routeNote
Vasostrict label1Post-cardiotomy vasodilatory shock0.03 to 0.1 units/minute, intravenousStarting dose 0.03 units/minute; titrated by 0.005 units/minute at 10- to 15-minute intervals
Vasostrict label1Septic shock0.01 to 0.07 units/minute, intravenousStarting dose 0.01 units/minute
Vasostrict label1Doses above the ranges aboveAbove 0.1 units/minute post-cardiotomy, above 0.07 units/minute septicThe label states there are limited data and adverse reactions are expected to increase
VASST, 20082Septic shock, 778 patients; against norepinephrine 5 to 15 microg per minute0.01 to 0.03 U per minute, infusion; route not stated in the record readMortality at 28 days
VANCS, 20173Vasoplegic shock after cardiac surgery, 300 infused; against norepinephrine 10 to 60 μg/min0.01 to 0.06 U/min; route not stated in the record readComposite outcome within 30 days
App's figureNone; no comparator1 IU, SubQNominal figure in the app, not a source figure

The label gives strengths in units per mL, for example "20 units/mL in a single dose vial", and states that "One mg is equivalent to 530 units."1

The label lists "decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital)" as the most common adverse reactions.1 It qualifies that these reactions "are reported voluntarily from a population of uncertain size", so "it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure".1 Other reactions named on the label include hemorrhagic shock, decreased platelets, intractable bleeding, right heart failure, atrial fibrillation, mesenteric ischemia, increased bilirubin levels, acute renal insufficiency, distal limb ischemia and ischemic lesions.1 The label warns that a "decrease in cardiac index may be observed with the use of vasopressin".1 It describes overdosage as expected to "manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia", and says direct effects "will resolve within minutes of withdrawal of treatment".1 For pregnancy, the label says the product "may produce tonic uterine contractions that could threaten the continuation of pregnancy", and that safety and effectiveness in pediatric patients with vasodilatory shock "have not been established".1 Among the interactions listed, drugs suspected of causing SIADH (for example SSRIs, tricyclic antidepressants, haloperidol and vincristine) "may increase the pressor effect in addition to the antidiuretic effect", and drugs suspected of causing diabetes insipidus (for example lithium and demeclocycline) may decrease the pressor effect.1 In the trials, serious adverse events were 10.3% with vasopressin and 10.5% with norepinephrine in VASST (P=1.00); VANCS reported atrial fibrillation in 63.8% with vasopressin against 82.1% with norepinephrine and no difference between groups in digital ischemia, mesenteric ischemia, hyponatremia and myocardial infarction; VANCS II reported no significant differences in adverse events; and the individual patient data meta-analysis found more digital ischaemia with vasopressin (absolute risk difference 1.7%, 95% CI 0.3%-3.2%) and fewer arrhythmias (-2.8%, 95% CI -0.2% to -5.3%), with mesenteric ischaemia and acute coronary syndrome events similar between groups.2,3,5,6

7

Bloodwork and markers

The app lists sodium as the marker to monitor.1 Hyponatremia appears on the label under metabolic adverse reactions and among the most common adverse reactions, and overdosage is expected to appear partly "as hyponatremia".1 In the other direction, the label states that patients "may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin", and that serum electrolytes, fluid status and urine output are to be monitored after discontinuation.1 In the Bradford retrospective study of infants, the median sodium nadir was 128.5 mEq/L in those who developed hyponatremia and 142.0 mEq/L in matched controls.7 In VANCS the authors report no difference between groups in the rate of hyponatremia.3

8

Regulatory and anti-doping status

The US label reads "Initial U.S. Approval: 2014" for Vasostrict and gives the single use in vasodilatory shock described above.1 Only the US label was read for approval status; labels or approvals in other jurisdictions and other indications were not searched.1 The World Anti-Doping Agency's 2026 Prohibited List text names "Desmopressin" in class S5 (diuretics and masking agents), and the word vasopressin does not appear in the text read.8 The S5 text is worded "Including, but not limited to" and extends to "other substances with a similar chemical structure or similar biological effect(s)".8 The list read does not name vasopressin itself, and no statement is made here about how WADA classifies vasopressin.

9

Storage and handling

Sources in this part

  1. 1Par Health USA, 2026

The label's storage statement is "Store between 2°C and 8°C (36°F and 46°F)", followed by "Do not freeze".1 It adds that vials "may be held up to 12 months upon removal from refrigeration to room temperature storage conditions" within the labeled shelf life, and that the refrigerated 10 mL multiple dose vial is discarded "after 30 days after first puncture".1

10

What is not known

No controlled trial of subcutaneous vasopressin in people was identified among the PubMed records matching "vasopressin subcutaneous administration randomized" (28 records matched, 20 listed, none a study of subcutaneous arginine vasopressin dosing). The app's 1 IU subcutaneous figure therefore has no study or label figure beside it in the sources read.1 The app's notes mention diabetes insipidus and gastrointestinal or variceal bleeding as hospital uses; the sources read cover vasodilatory shock, and uses outside shock were not searched. The three randomised trials described above report mortality or composite outcomes up to 90 days, and the meta-analysis authors state that its confidence intervals are wide and that future trials "focus on long-term outcomes in select patient groups".6 The label notes that clinical studies "did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects".1

What is the half-life of vasopressin?

The Vasostrict label gives an apparent half-life of 10 minutes or less at infusion rates used in vasodilatory shock, and the app lists 0.3 hours (about 18 minutes).1

How long does vasopressin take to reach its peak effect?

The label says the pressor effect reaches its peak within 15 minutes, and the app lists a time to peak of about 0.2 hours.1 The label adds that after the infusion stops "the pressor effect fades within 20 minutes", while the app lists a duration of 1 hour.1

Is vasopressin banned by WADA?

The 2026 WADA Prohibited List text read does not contain the word vasopressin; it names desmopressin in class S5.8 The S5 class is worded "Including, but not limited to", so the list read does not settle the question on its own.8

Is vasopressin FDA approved?

The US label for Vasostrict gives initial US approval in 2014, for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.1

What receptors does vasopressin act on?

The label names V1 receptors on vascular smooth muscle, which mediate vasoconstriction, and V2 receptors, which mediate antidiuresis.1

What is the bioavailability of vasopressin?

The app lists 100%, and the label text read gives no bioavailability figure; the label describes the product as being for intravenous use.1

Does vasopressin lower blood sodium?

Hyponatremia is listed on the label among the most common adverse reactions, and the label's frequency caveat is that reports come from "a population of uncertain size".1 In a retrospective study of infants after cardiac surgery, 20 of 142 (14.1%) developed hyponatremia, and each additional hour of vasopressin was associated with 5% higher odds.7

Did vasopressin lower mortality in septic shock trials?

In VASST, 28-day mortality was 35.4% with vasopressin and 39.3% with norepinephrine (P=0.26), which the authors report as no significant difference.2 The individual patient data meta-analysis of four trials reported a relative risk of 0.98 (95% CI 0.86-1.12) for 28-day mortality.6

13

References

  1. Par Health USA, LLC. Vasostrict (vasopressin) injection, for intravenous use. US prescribing information, DailyMed record version 49, 2026. DailyMed label
  2. Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008. PMID 18305265
  3. Hajjar LA, et al. Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial. Anesthesiology 2017. PMID 27841822
  4. University of Sao Paulo. Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery (VaNCS). ClinicalTrials.gov NCT01505231. NCT01505231
  5. Hajjar LA, et al. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial. Crit Care Med 2019. PMID 31609774
  6. Nagendran M, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med 2019. PMID 31062052
  7. Bradford CV, et al. Vasopressin-Induced Hyponatremia in Infants Following Cardiovascular Surgery. Ann Pharmacother 2023. PMID 35713009
  8. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list